Drug Profile
WIP DF17
Alternative Names: WIP-DF17Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Whanin Pharmaceutical
- Class Antidepressants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Depressive disorders
Most Recent Events
- 28 Jun 2022 Registered for Depressive disorders (In volunteers) in South Korea (PO) ((Whanin Pharmaceutical pipeline, June 2022)
- 27 Jul 2018 Early research in Depressive disorders in South Korea (unspecified route) (Whanin Pharmaceutical pipeline, July 2018)